References
- Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370:932–942.
- Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.
- Kaushik D, Boorjian SA, Thompson RH, et al. Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer. Int Braz J Urol. 2016;42:1091–1098.
- Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308.
- Fossa SD, Wiklund F, Klepp O, et al. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of The Scandinavian Prostate Cancer Group-7. Eur Urol. 2016;70:684–691.
- Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–2027.
- Dell'Oglio P, Karnes RJ, Joniau S, et al. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urol Oncol. 2016;34:234.e13–239.
- Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ (Clinical Research ed). 2014;348:g1502.
- Stattin P, Sandin F, Thomsen FB, et al. Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study. Eur Urol. 2017;72:125–134.
- D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974.
- Schelin S, Madsen M, Palmqvist E, et al. Long-term follow-up after triple treatment of prostate cancer stage pT3. Scand J Urol Nephrol. 2009;43:186–191.
- Fall K, Stromberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42:352–357.
- Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90:561–566.
- Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417–428.
- Jackson WC, Schipper MJ, Johnson SB, et al. Duration of androgen deprivation therapy influences outcomes for patients receiving radiation therapy following radical prostatectomy. Eur Urol. 2016;69:50–57.
- Rajan P, Sooriakumaran P, Nyberg T, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. JCO. 2017;35:3566–3574.
- Briganti A, Spahn M, Joniau S, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013;63:693–701.
- Lee JY, Kang HW, Rha KH, et al. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach. J Cancer Res Clin Oncol. 2016;142:849–858.
- Matthes KL, Limam M, Pestoni G, et al. Impact of comorbidities at diagnosis on prostate cancer treatment and survival. J Cancer Res Clin Oncol. 2018;144:707–715.
- Kishan AU, Cook RR, Ciezki JP, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer. JAMA. 2018;319:896–905.
- Hernandez DJ, Nielsen ME, Han M, et al. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology. 2007;70:931–935.
- Boorjian SA, Karnes RJ, Rangel LJ, et al. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008;179:1354–1360; discussion 1360–1361.